The fontan patient: Inconsistencies in medication therapy across seven pediatric heart network centers

Page A W Anderson, Roger E. Breitbart, Brian W. McCrindle, Lynn A. Sleeper, Andrew M. Atz, Daphne T. Hsu, Minmin Lu, Renee Margossian, Richard V. Williams

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Patients who have undergone the Fontan procedure are at risk for thrombosis, ventricular dysfunction, and valve regurgitation, but data to guide the medical treatment and prevention of these adverse outcomes in this population are lacking. This analysis examined medication usage among Fontan patients by putative indication and by study center. The medical history and current medications of 546 Fontan subjects, ages 6-18 years, were assessed in a Pediatric Heart Network multicenter cross-sectional study. Cardiac imaging was performed within 3 months of enrollment. The majority of the subjects (64%) were taking two or more medications. Antithrombotics were taken by 86% of those with a history of stroke, thrombosis, or both and 67% of those without such a history (P = 0.01). Conversely, 14% of those with a history of stroke, thrombosis, or both were taking no antithrombotic. Angiotensin-converting enzyme inhibitor (ACEi) therapy was independently associated with moderate or severe atrioventricular valve regurgitation (P = 0.004), right ventricular morphology (P < 0.001), and shorter time since Fontan (P = 0.004) but not with ventricular systolic dysfunction. Glycoside therapy and diuretic therapy each was associated with older age at Fontan (P = 0.001 and P = 0.023, respectively) and a history of post-Fontan arrhythmia (P < 0.001 and P = 0.003, respectively) but not with ventricular systolic dysfunction. Medication use rates varied widely among the centers, even with controls for center differences in patient characteristics. Prospective therapeutic trials are needed to guide the medical treatment of Fontan patients.

Original languageEnglish (US)
Pages (from-to)1219-1228
Number of pages10
JournalPediatric Cardiology
Volume31
Issue number8
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Ventricular Dysfunction
Pediatrics
Thrombosis
Stroke
Fontan Procedure
Enzyme Therapy
Therapeutics
Glycosides
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Cardiac Arrhythmias
Cross-Sectional Studies
History
Population

Keywords

  • Congenital
  • Drugs
  • Fontan procedure
  • Heart defects
  • Morbidity
  • Pediatrics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Anderson, P. A. W., Breitbart, R. E., McCrindle, B. W., Sleeper, L. A., Atz, A. M., Hsu, D. T., ... Williams, R. V. (2010). The fontan patient: Inconsistencies in medication therapy across seven pediatric heart network centers. Pediatric Cardiology, 31(8), 1219-1228. https://doi.org/10.1007/s00246-010-9807-5

The fontan patient : Inconsistencies in medication therapy across seven pediatric heart network centers. / Anderson, Page A W; Breitbart, Roger E.; McCrindle, Brian W.; Sleeper, Lynn A.; Atz, Andrew M.; Hsu, Daphne T.; Lu, Minmin; Margossian, Renee; Williams, Richard V.

In: Pediatric Cardiology, Vol. 31, No. 8, 11.2010, p. 1219-1228.

Research output: Contribution to journalArticle

Anderson, PAW, Breitbart, RE, McCrindle, BW, Sleeper, LA, Atz, AM, Hsu, DT, Lu, M, Margossian, R & Williams, RV 2010, 'The fontan patient: Inconsistencies in medication therapy across seven pediatric heart network centers', Pediatric Cardiology, vol. 31, no. 8, pp. 1219-1228. https://doi.org/10.1007/s00246-010-9807-5
Anderson, Page A W ; Breitbart, Roger E. ; McCrindle, Brian W. ; Sleeper, Lynn A. ; Atz, Andrew M. ; Hsu, Daphne T. ; Lu, Minmin ; Margossian, Renee ; Williams, Richard V. / The fontan patient : Inconsistencies in medication therapy across seven pediatric heart network centers. In: Pediatric Cardiology. 2010 ; Vol. 31, No. 8. pp. 1219-1228.
@article{1f8f9011c28645dfb1669da0339dcf25,
title = "The fontan patient: Inconsistencies in medication therapy across seven pediatric heart network centers",
abstract = "Patients who have undergone the Fontan procedure are at risk for thrombosis, ventricular dysfunction, and valve regurgitation, but data to guide the medical treatment and prevention of these adverse outcomes in this population are lacking. This analysis examined medication usage among Fontan patients by putative indication and by study center. The medical history and current medications of 546 Fontan subjects, ages 6-18 years, were assessed in a Pediatric Heart Network multicenter cross-sectional study. Cardiac imaging was performed within 3 months of enrollment. The majority of the subjects (64{\%}) were taking two or more medications. Antithrombotics were taken by 86{\%} of those with a history of stroke, thrombosis, or both and 67{\%} of those without such a history (P = 0.01). Conversely, 14{\%} of those with a history of stroke, thrombosis, or both were taking no antithrombotic. Angiotensin-converting enzyme inhibitor (ACEi) therapy was independently associated with moderate or severe atrioventricular valve regurgitation (P = 0.004), right ventricular morphology (P < 0.001), and shorter time since Fontan (P = 0.004) but not with ventricular systolic dysfunction. Glycoside therapy and diuretic therapy each was associated with older age at Fontan (P = 0.001 and P = 0.023, respectively) and a history of post-Fontan arrhythmia (P < 0.001 and P = 0.003, respectively) but not with ventricular systolic dysfunction. Medication use rates varied widely among the centers, even with controls for center differences in patient characteristics. Prospective therapeutic trials are needed to guide the medical treatment of Fontan patients.",
keywords = "Congenital, Drugs, Fontan procedure, Heart defects, Morbidity, Pediatrics",
author = "Anderson, {Page A W} and Breitbart, {Roger E.} and McCrindle, {Brian W.} and Sleeper, {Lynn A.} and Atz, {Andrew M.} and Hsu, {Daphne T.} and Minmin Lu and Renee Margossian and Williams, {Richard V.}",
year = "2010",
month = "11",
doi = "10.1007/s00246-010-9807-5",
language = "English (US)",
volume = "31",
pages = "1219--1228",
journal = "Pediatric Cardiology",
issn = "0172-0643",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - The fontan patient

T2 - Inconsistencies in medication therapy across seven pediatric heart network centers

AU - Anderson, Page A W

AU - Breitbart, Roger E.

AU - McCrindle, Brian W.

AU - Sleeper, Lynn A.

AU - Atz, Andrew M.

AU - Hsu, Daphne T.

AU - Lu, Minmin

AU - Margossian, Renee

AU - Williams, Richard V.

PY - 2010/11

Y1 - 2010/11

N2 - Patients who have undergone the Fontan procedure are at risk for thrombosis, ventricular dysfunction, and valve regurgitation, but data to guide the medical treatment and prevention of these adverse outcomes in this population are lacking. This analysis examined medication usage among Fontan patients by putative indication and by study center. The medical history and current medications of 546 Fontan subjects, ages 6-18 years, were assessed in a Pediatric Heart Network multicenter cross-sectional study. Cardiac imaging was performed within 3 months of enrollment. The majority of the subjects (64%) were taking two or more medications. Antithrombotics were taken by 86% of those with a history of stroke, thrombosis, or both and 67% of those without such a history (P = 0.01). Conversely, 14% of those with a history of stroke, thrombosis, or both were taking no antithrombotic. Angiotensin-converting enzyme inhibitor (ACEi) therapy was independently associated with moderate or severe atrioventricular valve regurgitation (P = 0.004), right ventricular morphology (P < 0.001), and shorter time since Fontan (P = 0.004) but not with ventricular systolic dysfunction. Glycoside therapy and diuretic therapy each was associated with older age at Fontan (P = 0.001 and P = 0.023, respectively) and a history of post-Fontan arrhythmia (P < 0.001 and P = 0.003, respectively) but not with ventricular systolic dysfunction. Medication use rates varied widely among the centers, even with controls for center differences in patient characteristics. Prospective therapeutic trials are needed to guide the medical treatment of Fontan patients.

AB - Patients who have undergone the Fontan procedure are at risk for thrombosis, ventricular dysfunction, and valve regurgitation, but data to guide the medical treatment and prevention of these adverse outcomes in this population are lacking. This analysis examined medication usage among Fontan patients by putative indication and by study center. The medical history and current medications of 546 Fontan subjects, ages 6-18 years, were assessed in a Pediatric Heart Network multicenter cross-sectional study. Cardiac imaging was performed within 3 months of enrollment. The majority of the subjects (64%) were taking two or more medications. Antithrombotics were taken by 86% of those with a history of stroke, thrombosis, or both and 67% of those without such a history (P = 0.01). Conversely, 14% of those with a history of stroke, thrombosis, or both were taking no antithrombotic. Angiotensin-converting enzyme inhibitor (ACEi) therapy was independently associated with moderate or severe atrioventricular valve regurgitation (P = 0.004), right ventricular morphology (P < 0.001), and shorter time since Fontan (P = 0.004) but not with ventricular systolic dysfunction. Glycoside therapy and diuretic therapy each was associated with older age at Fontan (P = 0.001 and P = 0.023, respectively) and a history of post-Fontan arrhythmia (P < 0.001 and P = 0.003, respectively) but not with ventricular systolic dysfunction. Medication use rates varied widely among the centers, even with controls for center differences in patient characteristics. Prospective therapeutic trials are needed to guide the medical treatment of Fontan patients.

KW - Congenital

KW - Drugs

KW - Fontan procedure

KW - Heart defects

KW - Morbidity

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=78449295408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449295408&partnerID=8YFLogxK

U2 - 10.1007/s00246-010-9807-5

DO - 10.1007/s00246-010-9807-5

M3 - Article

C2 - 20938655

AN - SCOPUS:78449295408

VL - 31

SP - 1219

EP - 1228

JO - Pediatric Cardiology

JF - Pediatric Cardiology

SN - 0172-0643

IS - 8

ER -